Description

The Glomerular Diseases: 2025 Update was a full-day Early Program held on the Wednesday immediately preceding the main ASN Kidney Week 2025 Annual Meeting.

This course is consistently one of the most popular early programs, designed to be a “one-stop shop” for updates on glomerular pathology. The 2025 edition focused on the explosion of new therapeutic options, particularly for IgA Nephropathy (IgAN) and Lupus Nephritis, helping clinicians navigate the increasingly crowded landscape of B-cell therapies and complement inhibitors.

What You Will Learn

The curriculum was designed to update the “mental models” of clinicians regarding disease pathogenesis and treatment. Key learning outcomes included:

IgA Nephropathy Revolution: How to choose between the multiple new FDA-approved options (e.g., endothelin receptor antagonists vs. B-cell depleters vs. complement inhibitors) based on patient profiles.

Lupus Nephritis (LN): Interpreting the 2024 KDIGO Guidelines update, specifically regarding the timing of “add-on” therapies (like voclosporin or belimumab) to standard of care.

The “Podocytopathy” Reclassification: Moving away from “FSGS” and “MCD” toward a molecular classification based on autoantibodies (e.g., anti-nephrin) and gene

tic drivers.